Here's a biotech story that's part science, part business, and now part artificial intelligence. Hoth Therapeutics Inc. (HOTH) announced it's bringing in some silicon-based help to advance its experimental cancer drug. The company said it has integrated OpenAI's API into its development workflow for a therapy called HT-KIT, which targets rare and aggressive cancers driven by a protein called KIT.
Think of it as giving the research team a very smart, very fast assistant. The AI platform is being used to crunch preclinical data, model complex molecular pathways, and—perhaps most bureaucratically important—help prepare the mountain of documentation needed to ask regulators for permission to start testing in humans. That's the Investigational New Drug (IND) submission, a critical gate every drug candidate must pass through.
So, what's this drug that's getting the AI treatment? The early data for HT-KIT looks promising. In lab and animal models of two tough cancers—systemic mastocytosis and gastrointestinal stromal tumors (GIST)—the therapy achieved a reduction of over 80% in the KIT mRNA and protein that fuel the diseases. Perhaps just as crucial, researchers haven't seen any dose-limiting toxicities in the preclinical work to date. In animal models, a statistically significant reduction in tumor volume was seen by day eight, with cell death signaling consistent with knocking down the KIT pathway.
The company has completed the necessary analytical methods to support pharmacokinetic studies and is pushing HT-KIT toward that all-important IND submission and eventual Phase 1 clinical trials. The therapy has already received Orphan Drug Designation, which provides certain incentives for developing treatments for rare diseases.
This isn't the only program Hoth has been working on. Back in February, the company revealed preclinical data for a different compound targeting obesity and metabolic liver disease. In a head-to-head study, Hoth's glial cell-derived neurotrophic factor (GDNF) showed superior efficacy to Novo Nordisk A/S's (NVO) blockbuster drugs Wegovy and Ozempic (semaglutide) in several key metrics in female animal models. Those metrics included weight stabilization, glucose tolerance, and reduction in liver weight.
In January, Hoth shared interim results from another ongoing trial, CLEER-001, which is evaluating a topical formulation called HT-001 for skin reactions in cancer patients. In an open-label group, 100% of evaluable patients achieved a clinical response by week six, with disease severity scores dropping by about 50% from baseline.
The latest update on HT-KIT builds on findings shared last September, which showed the therapy triggered significant tumor cell death in models of GIST and systemic mastocytosis as early as 24 hours after treatment.
Hoth Therapeutics stock closed at $0.997 on Tuesday.
